Showing 20 of 223 recruiting trials for “acute-promyelocytic-leukemia”
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
👨⚕️ Matthew J Wieduwilt, Alliance for Clinical Trials in Oncology📍 271 sites📅 Started May 2019View details ↗
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
👨⚕️ Prof. Dr. Michael Schmitt, University Hospital Heidelberg, Department V📍 2 sites📅 Started Sep 2018View details ↗
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML
RecruitingNCT03568266 ↗
Pharmacogenomics of Asparaginase Induced Hepatotoxicity
👨⚕️ Houda Alachkar, Ph.D., University of Southern California📍 1 site📅 Started May 2018View details ↗
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
👨⚕️ Brenda M. Sandmaier, Fred Hutch/University of Washington Cancer Consortium📍 1 site📅 Started Oct 2017View details ↗
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
👨⚕️ Leland Metheny, MD, University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center📍 7 sites📅 Started Jul 2017View details ↗
CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia
Ibrutinib and Blinatumomab in Treating Patients With Relapsed or Refractory B Acute Lymphoblastic Leukemia
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
CARPALL: Immunotherapy with CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic Leukaemia
RecruitingNCT03275480 ↗
Institut Paoli Calmettes Myelodysplastic Syndromes Database
KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children
👨⚕️ Michael Pulsipher, MD, Children's Hospital Los Angeles📍 11 sites📅 Started Oct 2015View details ↗
ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)
👨⚕️ Christina Peters, Prof. MD PhD, St. Anna Kinderspital, Vienna, Austria📍 4 sites📅 Started Apr 2013View details ↗
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →